Showing 1 - 4 of 4
New drug to be registered with FDA
News, Apinya Wipatayotin, Published on 04/07/2025
» The Government Pharmaceutical Organisation (GPO) has prepared to register the affordable hepatitis C drug ravidasvir with the Food and Drug Administration to improve access for 800,000 patients and reduce treatment costs.
Unite to solve neglected diseases
Oped, Muhammad Radzi Abu Hassan, Published on 29/04/2025
» The successful collaboration between the health ministries of Malaysia and Thailand, industry partners in Egypt and Malaysia, and the Drugs for Neglected Diseases initiative (DNDi) to bring a new hepatitis C antiviral drug -- ravidasvir -- to market in 2022 was an important milestone. For years, a 12-week course of treatment using sofosbuvir cost between $70,000 (2.34 million baht) and $80,000, putting it out of reach for many in the Global South. But ravidasvir -- a safe and effective alternative when combined with sofosbuvir -- costs far less, averaging less than $500 per course.
Hep C meds urged for HIV patients
News, Post Reporters, Published on 28/07/2018
» Health networks have called on authorities to ensure patients with HIV/Aids have more access to medicine for the treatment of hepatitis C.
Low-cost Hep C cure showing good results
News, Apinya Wipatayotin, Published on 08/05/2018
» The first phase of clinical tests for an affordable Hepatitis C treatment has yielded a high cure rate, according to the Department of Disease Control.